Research Topics
Species | P PrandoniSummaryCountry: Italy Publications
| Collaborators
|
Detail Information
Publications
Heparins and venous thromboembolism: current practice and future directionsP Prandoni
Clinica Medica II, University of Padua, Italy
Thromb Haemost 86:488-98. 2001..The efficacy and safety of pentasaccharide (the smallest antithrombin binding sequence of heparin) in the treatment and prevention of venous thromboembolic disorders is currently under investigation...
The optimal treatment of venous thrombosis: current status and future perspectivesP Prandoni
Clinica Medica II, University of Padua, Italy
Clin Lab 47:151-4. 2001..These objectives are satisfactorily achieved with anticoagulant drugs (heparin and vitamin K antagonists), which therefore are the mainstays of DVT treatment. Other therapeutic options have a more limited application...
Cancer and thromboembolic disease: how important is the risk of thrombosis?Paolo Prandoni
Clinica Medica II, University of Padua, Italy
Cancer Treat Rev 28:133-6. 2002..Extensive screening for cancer in patients with idiopathic venous thrombosis allows early detection of malignancies and identification of malignancy at an early stage...
The diagnostic value of compression ultrasonography in patients with suspected recurrent deep vein thrombosisPaolo Prandoni
Department of Medical and Surgical Sciences, University of Padua Medical School, Italy
Thromb Haemost 88:402-6. 2002..In conclusion, it is safe to withhold anticoagulant treatment from patients with suspected recurrent ipsilateral DVT in whom compression ultrasonography showed improved or stable vein diameters...
Residual venous thrombosis as a predictive factor of recurrent venous thromboembolismPaolo Prandoni
Department of Medical and Surgical Sciences, University of Padua, Via Ospedale Civile 105, 35128 Padua, Italy
Ann Intern Med 137:955-60. 2002..Contributing to the controversy is uncertainty about whether residual venous thrombosis, as assessed by repeated ultrasonography over time, increases the risk for recurrent thromboembolism...
An association between atherosclerosis and venous thrombosisPaolo Prandoni
Department of Medical and Surgical Sciences, Second Chair of Internal Medicine, University of Padua Medical School, Padua, Italy
N Engl J Med 348:1435-41. 2003..Whether atherosclerosis is associated with an increased risk of venous thrombosis is unknown...
Low molecular weight heparins: are they interchangeable? YesP Prandoni
Department of Medical and Surgical Sciences, University of Padua Medical School, Padua, Italy
J Thromb Haemost 1:10-1. 2003
Management of thrombosis in patients with hematologic malignanciesAndrea Piccioli
University of Padova, Via Ospedale Civile 105, Padova 35128, Italy
Curr Hematol Rep 1:79-83. 2002..Further work is needed to provide physicians with specific guidelines for a systematic management of thrombosis in patients with hematologic malignancies...
Long-term clinical course of proximal deep venous thrombosis and detection of recurrent thrombosisP Prandoni
Department of Clinical and Surgical Sciences, University of Padua, Italy
Semin Thromb Hemost 27:9-13. 2001..Recent data suggest that these patients can be safely managed with the use of serial compression ultrasonography...
Upper extremity deep vein thrombosisP Prandoni
Department of Medical and Surgical Sciences, University of Padua Medical School, Italy
Curr Opin Pulm Med 5:222-6. 1999..This review suggests that upper extremity deep-vein thrombosis is at least as serious a disease entity as deep-vein thrombosis of the lower extremities...
Cancer and venous thromboembolism: an overviewP Prandoni
Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, Via Ospedale Civile 105, 35128 Padua, Italy
Haematologica 84:437-45. 1999..The aim of this study was to review briefly the mechanisms by which cancer may induce the development of thrombosis and to analyze critically the most recent clinical advances in this field...
Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized studyPaolo Prandoni
Department of Medical and Surgical Sciences, Second Chair of Internal Medicine, University Hospital of Padua, Via Ospedale Civile 105, 35128 Padua, Italy
Arch Intern Med 162:1966-71. 2002..Although oral anticoagulants are still widely used for the prevention of venous thromboembolism after hip replacement, to our knowledge no study has assessed the benefit of prolonging anticoagulation beyond the hospital stay...
The incidence of venous thromboembolism in carriers of antithrombin, protein C or protein S deficiency associated with the HR2 haplotype of factor V: a family cohort studyD Tormene
Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, University of Padua Medical School, Padua, Italy
J Thromb Haemost 3:1414-20. 2005..0%) and none in 147 non-carriers. In family members of patients with AT, PC or PS defects the coinheritance of HR2 haplotype does not seem to increase the thromboembolic risk...
Upper extremity deep vein thrombosis: risk factors, diagnosis, and managementE Bernardi
Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, University of Padua Medical School, Padua, Italy
Semin Vasc Med 1:105-10. 2001..Prophylaxis with low-dose heparin or low-dose warfarin is necessary whenever central venous catheters are positioned...
The optimal duration of anticoagulation in patients with venous thromboembolism: how long is long enough?P Prandoni
Department of Cardiothoracic and Vascular Sciences, Clinica Medica II and Thromboembolism Unit, University of Padua, Padua, Italy
Panminerva Med 54:39-44. 2012....
Factor V Leiden mutation and the risk of venous thromboembolism in pregnant womenD Tormene
Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, University of Padua Medical School, Via Ospedale Civile 105, 35128 Padua, Italy
Haematologica 86:1305-9. 2001....
Diagnosis of recurrent deep vein thrombosisP Prandoni
Department of Medical and Surgical Sciences, University of Padua Medical School, Padua, Italy
Semin Vasc Med 1:55-60. 2001..The safety of withholding anticoagulants from patients with a normal quantitative CUS work-up has been recently demonstrated in a prospective management study...
Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysisB Girolami
Institute of Medical Semeiotics, University Hospital of Padua, Italy
Arch Intern Med 159:337-45. 1999..There is no consensus on the efficacy of physical training, smoking cessation, and pharmacological therapy (pentoxifylline or nafronyl oxalate) in the treatment of patients with intermittent claudication at Fontaine stage II of disease...
Prevention of venous thromboembolism in high-risk surgical and medical patientsP Prandoni
Department of Medical and Surgical Sciences, University of Padua Medical School, Padua, Italy
Semin Vasc Med 1:61-70. 2001..In a recent controlled randomized trial, enoxaparin in high prophylactic doses was an effective and safe measure of thromboprophylaxis in ordinary bedridden patients...
[Therapeutic indications for acute venous thromboembolism. Current status and future perspectives]P Prandoni
Clinica Medica II, , Padova, Italy
Minerva Cardioangiol 51:361-71. 2003..The efficacy and safety of emerging drugs (pentasaccharide, ximelagatran) in the treatment and secondary prevention of venous thromboembolic disorders is currently under investigation...
The value of 64-detector row computed tomography for the exclusion of pulmonary embolismR Pesavento
Department of Cardiothoracic and Vascular Sciences, 2nd chair of Internal Medicine and Thromboembolism Unit, University of Padua, Padua, Italy
Thromb Haemost 105:901-7. 2011..0 to 1.51%) and none developed PE (0 %; 95%CI, 0 to 1.0%). We conclude that 64-DCT scanning has the potential to safely exclude the presence of PE virtually in all patients presenting with clinical suspicion of this clinical disorder...
Venous thromboembolism and the risk of subsequent symptomatic atherosclerosisP Prandoni
Department of Medical and Surgical Sciences, University Hospital of Padua, Padua, Italy
J Thromb Haemost 4:1891-6. 2006..We hypothesized that patients with VTE of unknown origin would be at a higher risk of developing symptomatic atherosclerosis than patients with VTE induced by known risk factors...
The value of ultrasound screening for proximal vein thrombosis after total hip arthroplasty--a prospective cohort studyF Verlato
Unit Care of Angiology, University Hospital of Padua, Italy
Thromb Haemost 86:534-7. 2001..A larger controlled study in which the value of this strategy is tested against the prolongation of oral anticoagulation in patients with a negative ultrasound screening at discharge is indicated...
Postthrombotic syndrome: incidence, prevention, and managementE Bernardi
Department of Medical and Surgical Sciences, University of Padua Medical School, Padua, Italy
Semin Vasc Med 1:71-80. 2001..Clinical presentation has a prognostic value, as patients with initially severe symptoms enjoy a more favorable outcome than those who progressively deteriorate over time...
A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction ScoreS Barbar
Department of Cardiothoracic and Vascular Sciences, Second Division of Internal Medicine, University of Padua, Padova, Italy
J Thromb Haemost 8:2450-7. 2010..Prophylaxis of venous thromboembolism (VTE) in hospitalized medical patients is largely underused. We sought to assess the value of a simple risk assessment model (RAM) for the identification of patients at risk of VTE...
Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trialA Piccioli
Department of Medical and Surgical Sciences, Second Division of Internal Medicine, University of Padua, Italy
J Thromb Haemost 2:884-9. 2004..9%) of the 102 control patients [absolute difference, 1.9% (95% CI, -5.5-10.9)]. Although early detection of occult cancers may be associated with improved treatment possibilities, it is uncertain whether this improves the prognosis...
Venous thromboembolism as first manifestation of cancerA Piccioli
Clinica Medica II, University Hospital of Padua, Via Ospedale Civile 105, I-35128 Padua, Italy
Acta Haematol 106:13-7. 2001..Proper clinical trials are being conducted to find an answer to these questions...
Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort studyA Cogo
Istituto di Semeiotica Medica, University of Padua, Italy
BMJ 316:17-20. 1998..8. CONCLUSION: It is safe to withhold anticoagulant treatment from patients with clinically suspected deep vein thrombosis who have a normal result on compression ultrasonography at the time of presentation and at 1 week...
Circulating microparticles in carriers of factor V Leiden with and without a history of venous thrombosisElena Campello
Department of Cardiologic, Thoracic, and Vascular Sciences, 2nd Chair of Internal Medicine, University of Padua Medical School, Padua, Italy
Thromb Haemost 108:633-9. 2012..005). Our study results suggest that circulating MP may contribute to the development of thrombosis in carriers of FVL mutation...
Antithrombotic drugs in the primary medical management of intermittent claudication: a meta-analysisB Girolami
Institute of Medical Semeiotics, University Hospital of Padua, Italy
Thromb Haemost 81:715-22. 1999..There is no consensus on the efficacy of the antithrombotic drugs available for patients with intermittent claudication...
Idiopathic venous thromboembolism as a first manifestation of cancerA Piccioli
Department of Medical and Surgical Sciences, University of Padua, Italy
Haemostasis 31:37-9. 2001....
High vs. low doses of low-molecular-weight heparin for the treatment of superficial vein thrombosis of the legs: a double-blind, randomized trialP Prandoni
Department of Medical and Surgical Sciences, University of Padova, Italy
J Thromb Haemost 3:1152-7. 2005....
New anticoagulants for the treatment of venous thromboembolismP Prandoni
Department of Cardiothoracic and Vascular Sciences, University of Padua, Padua, Italy
Minerva Med 104:131-40. 2013..Both of them have limitations for the treatment of patients with severe renal failure, and require further investigations in cancer patients and in pregnant patients with VTE. Both of them lack an antidote...
Links between arterial and venous diseaseP Prandoni
Department of Medical and Surgical Sciences, Thromboembolism Unit, University Hospital of Padua, Padua, Italy
J Intern Med 262:341-50. 2007..Future studies are needed to clarify the nature of this association, to assess its extent and to evaluate its implications for clinical practice...
Screening for occult cancer in patients with idiopathic venous thromboembolism: yesA Piccioli
Department of Medical and Surgical Sciences, University of Padua, Italy
J Thromb Haemost 1:2271-2. 2003
Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosisP Simioni
Department of Medical and Surgical Sciences, Second Chair of Internal Medicine, University Hospital of Padua, Italy
Blood 96:3329-33. 2000..2 to 30.1) in patients without the mutations. Prothrombin and factor V gene mutations occur frequently in patients with venous thrombosis and are associated with an increased risk for recurrent venous thromboembolic complications...
Prevention of thromboembolic complications in patients with atrial fibrillationL Spiezia
Department of Cardiac, Thoracic and Vascular Sciences, 2nd Chair of Internal Medicine, University of Padua, Padua, Italy
Minerva Cardioangiol 56:643-52. 2008....
Venous thromboembolism and atherosclerosis: is there a link?P Prandoni
Department of Medical and Surgical Sciences, Thromboembolism Unit, University Hospital of Padua, Padua, Italy
J Thromb Haemost 5:270-5. 2007..In conclusion, the separate nature of arterial and venous disorders has been challenged. Future studies are needed to clarify the nature of this association, to assess its extent, and to evaluate its implications for clinical practice...
Aspirin and recurrent venous thromboembolismP Prandoni
Department of Cardiothoracic and Vascular Sciences, Clinica Medica 2, Via Giustiniani 2, 35128 Padua, Italy
Phlebology 28:99-104. 2013..Conversely, aspirin in low doses offers an appealing, safe and highly cost-effective option for the long-term prevention of recurrent events in patients with unprovoked VTE who are free from symptomatic atherosclerotic lesions...
Cancer and venous thromboembolismAndrea Piccioli
Department of Medical and Surgical Sciences, University of Padua, Padua, Italy
Semin Thromb Hemost 32:694-9. 2006..Anticoagulant drugs appear to be an attractive strategy in cancer treatment because there is growing evidence for their possible benefits in terms of cancer prognosis and patient survival...
Superficial vein thrombosis: risk factors, diagnosis, and treatmentAntonio Marchiori
Department of Emergency Medicine, S Anthony Hospital, Padua, Italy
Semin Thromb Hemost 32:737-43. 2006....
Heparin- induced thrombocytopenia occurring in the first trimester of pregnancy: successful treatment with lepirudin. A case reportAnna Furlan
University of Padua Medical School, Padova, Italy
Haematologica 91:ECR40. 2006....
Anticoagulants and cancer survivalAndrea Piccioli
Department of Medical and Surgical Sciences, Department of Internal Medicine, University of Padova, Italy
Semin Thromb Hemost 32:810-3. 2006..Additional clinical trials are needed to provide an important step forward in this challenging setting...
Incidence of arterial cardiovascular events in patients with idiopathic venous thromboembolism. A retrospective cohort studyCarlo Bova
Department of Medicine, Azienda Ospedaliera, Cosenza, Italy
Thromb Haemost 96:132-6. 2006..4 deaths). In conclusion, arterial events are more common in patients with previous idiopathic VTE than in the general population. These findings may have practical implications...
Thrombosis as a harbinger of cancerPaolo Prandoni
Department of Medical and Surgical Sciences, University of Padua, Padua, Italy
Curr Opin Hematol 13:362-5. 2006..The aim of this review is to explore the state of the art knowledge on the possible association between venous thromboembolism, especially idiopathic venous thromboembolism, and occult cancer, and to speculate on its implications...
Acquired risk factors of venous thromboembolism in medical patientsPaolo Prandoni
Department of Medical and Surgical Sciences 2nd Chair of Internal Medicine University of Padua, Italy
Pathophysiol Haemost Thromb 35:128-32. 2006..Recognition of the incidence and clinical importance of thrombosis will most likely encourage more widespread use of antithrombotic prophylaxis in medical patients...
Cancer and venous thromboembolism. Clinical implications of strong associationPaolo Prandoni
Department of Medical and Surgical Sciences 2nd Chair of Internal Medicine University of Padua, Italy
Pathophysiol Haemost Thromb 35:111-5. 2006..However, whether screening for occult malignancies ultimately improves prognosis and prolongs survival remains to be demonstrated...
Double vena cava filter insertion in congenital duplicated inferior vena cava: a case report and literature reviewMaria Teresa Sartori
Department of Medical and Surgical Sciences, University Hospital, Padua, Italy
Haematologica 91:ECR30. 2006..A filter had to be inserted in each vena cava to prevent pulmonary embolism. A review of the literature dealing with the few reported cases of filter insertion in congenital duplicated IVC is presented...
Thrombophilia as a predictor of persistent residual vein thrombosisLuca Spiezia
Haematologica 93:479-80. 2008..49 (95% CI, 0.38 to 0.63). These findings suggest that thrombophilia is an independent predictor of persistent residual vein thrombosis...
Postthrombotic syndromeRaffaele Pesavento
Department of Medical and Surgical Sciences, University of Padua, Padua, Italy
Semin Thromb Hemost 32:744-51. 2006..Clinical presentation helps predict the prognosis; the outcome of patients who refer with initially severe manifestations is more favorable than that of patients whose symptoms deteriorate progressively over time...
The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolismJames D Douketis
McMaster University, Hamilton, Ontario, Canada
Ann Intern Med 147:766-74. 2007..The long-term risk for fatal pulmonary embolism (PE) after treatment of venous thromboembolism (VTE) may be an important factor in the decision to discontinue this treatment...
Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort studyHenrik Toft Sørensen
Department of Clinical Epidemiology, Aarhus University Hospital, 8000 Aarhus C, Denmark
Lancet 370:1773-9. 2007..Other studies, however, do not show this association. To help clarify these discrepant findings, we aimed to investigate the risk of arterial cardiovascular events in patients who were diagnosed with venous thromboembolism...
Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patientsPaolo Prandoni
Department of Medical and Surgical Sciences, Thromboembolism Unit, University of Padua, Padua, Italy
Br J Haematol 141:587-97. 2008..Recognition of the incidence and clinical importance of thrombosis will probably encourage more widespread use of antithrombotic prophylaxis in medical patients and especially in some particular types of malignancies...
Should cancer patients receive thromboprophylaxis to prevent catheter-related upper limb deep vein thrombosis?Paolo Prandoni
Department of Medical and Surgical Sciences, University of Padua, Padua, Italy
Intern Emerg Med 3:85-6. 2008
Idraparinux: review of its clinical efficacy and safety for prevention and treatment of thromboembolic disordersPaolo Prandoni
Department of Medical and Surgical Sciences, Thromboembolism Unit, University of Padua, 35128 Padua, Italy
Expert Opin Investig Drugs 17:773-7. 2008..Idraparinux is a synthetic pentasaccharide that binds to antithrombin with high affinity. In view of its long half-life, it is suitable for once-a-week administration...
Low-molecular-weight heparin versus compression stockings for thromboprophylaxis after knee arthroscopy: a randomized trialGiuseppe Camporese
Unit of Angiology, University Hospital of Padua, Padua, Italy
Ann Intern Med 149:73-82. 2008..Knee arthroscopy, the most common orthopedic operation worldwide, carries a definite risk for deep venous thrombosis; however, postsurgical thromboprophylaxis is not routinely recommended...
The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studiesAntonio Marchiori
Department of Emergency Medicine, St Anthony Hospital, University of Padua, Padua, Italy
Haematologica 92:1107-14. 2007..The risk is lower with PTM and is difficult to interpret since it varies according to the assessment method used...
The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patientsPaolo Prandoni
Department of Medical and Surgical Sciences, University of Padua, Via Ospedale Civile 105, 35128, Padua, Italy
Haematologica 92:199-205. 2007..The aim of this investigation was to assess the rate of recurrent VTE after withdrawal of vitamin K antagonists, and to identify clinical parameters associated with a higher likelihood of recurrence...
Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE RegistryJavier Trujillo-Santos
Departament of Internal Medicine, Hospital Universitario Santa Maria de Rosell, Cartagena, Murcia, Spain
Thromb Haemost 100:435-9. 2008..2; 95% CI: 1.5-3.4), had an increased incidence of major bleeding. With some variables available at entry we may identify those cancer patients with VTE at a higher risk for recurrences or major bleeding...
New strategies for the treatment of acute venous thromboembolismPaolo Prandoni
Department of Medical and Surgical Sciences, University of Padua, Italy
Semin Thromb Hemost 32:787-92. 2006..Finally, new categories of drugs are emerging that have the potential to replace conventional anticoagulants in the near future. They include compounds that inhibit factor Xa or thrombin...
Does hemophilia protect against atherosclerosis? A case-control studyFranca Bilora
Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, University of Padua Medical School, Padua, Italy
Clin Appl Thromb Hemost 12:193-8. 2006..In all the examined districts, the mean IMT was significantly lower in patients with hemophilia than in controls. Hemophilia protects against asymptomatic atherosclerosis...
Low-molecular-weight heparins for the long-term treatment of cancer patients with venous thromboembolismPaolo Prandoni
Department of Medical and Surgical Sciences, University of Padua, Italy
J Support Oncol 4:127-8. 2006
Venous thromboembolism risk and management in women with cancer and thrombophiliaPaolo Prandoni
Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, Padua, Italy
Gend Med 2:S28-34. 2005..Venous thromboembolism (VTE) and its complications result in a high rate of morbidity and mortality...
Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolismPaolo Prandoni
Department of Medical and Surgical Sciences, University of Padua, Via Ospedale Civile 105, 35128 Padua, Italy
Arch Intern Med 164:1077-83. 2004..Few reports have addressed the value of unfractionated heparin (UFH) or low-molecular-weight heparin in treating the full spectrum of patients with venous thromboembolism (VTE), including recurrent VTE and pulmonary embolism...
Recurrent thromboembolism in cancer patients: incidence and risk factorsPaolo Prandoni
Department of Medical and Surgical Sciences, University of Padua, Via Ospedale Civile, 105, Padua, I 35128, Italy
Semin Thromb Hemost 29:3-8. 2003..In view of the persisting high risk for recurrent thrombotic events in cancer patients, and the acceptable risk of bleeding, prolonged warfarin treatment should be considered in such patients for as long as the cancer is active...
An antifibrinolytic effect associated with an anti-factor V antibody in a patient with severe thrombophiliaMario Colucci
Department of Biomedical Sciences, University of Bari, Italy
Haematologica 88:1383-9. 2003..Since activated protein C (APC) is also profibrinolytic we wanted to determine whether the presence of antibodies interfering with the anticoagulant activity of APC also inhibits its profibrinolytic effect...
Recurrent thromboembolism in fertile women with venous thrombosis: incidence and risk factorsLuca Spiezia
Thromb Haemost 90:964-6. 2003
Safety of low molecular weight heparins in the treatment of venous thromboembolismEnrico Bernardi
Pronto Soccorso, Azienda Ospedaliera di Padova, Via Giustiniani, N 1, 35128 Padova, Italy
Expert Opin Drug Saf 2:87-94. 2003....
Extended oral anticoagulant therapy after a first episode of pulmonary embolismGiancarlo Agnelli
Sezione di Medicina Interna e Cardiovascolare, Dipartimento di Medicina Interna, Universita di Perugia, Via Enrico Dal Pozzo, 06123 Perugia, Italy
Ann Intern Med 139:19-25. 2003..The optimal duration of oral anticoagulant treatment after a first episode of pulmonary embolism remains uncertain...
The treatment of venous thromboembolic disorders: new challenges and opportunitiesPaolo Prandoni
Dipartimento di Scienze Mediche e Chirurgiche, Clinica Medica II, , Padua, Italy
Haematologica 88:610-3. 2003
[Profiles of medical malpractice in the prophylaxis of pulmonary thromboembolism]Massimo Montisci
Dipartimento di Medicina Ambientale e Sanità Pubblica Sede di Medicina Legale e delle Assicurazioni Università degli Studi Via Falloppio, 50 35121 Padova
Ital Heart J Suppl 4:217-25. 2003....
The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort studyBruno Girolami
Division of Internal Medicine, Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, University Hospital of Padua, Italy
Blood 101:2955-9. 2003..Although the frequency of HIT in hospitalized medical patients treated with subcutaneous heparin is lower than that observed in other clinical settings, this complication is associated with a similarly high rate of thromboembolic events...
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosisPaolo Prandoni
Department of Medical and Surgical Sciences, Second Chair of Internal Medicine, University Hospital of Padua, Italy
Blood 100:3484-8. 2002..These risks correlate with the extent of cancer. Possibilities for improvement using the current paradigms of anticoagulation seem limited and new treatment strategies should be developed...
The incidence of venous thromboembolism in thrombophilic children: a prospective cohort studyDaniela Tormene
Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, University of Padua Medical School, Padua, Italy
Blood 100:2403-5. 2002..Accordingly, screening for thrombophilia in otherwise healthy children younger than 15 years who belong to families with inherited defects predisposing to thrombosis seems unjustified...
What is the role for antithrombotics in cancer care? Interactive session with panel discussionAjay K Kakkar
Imperial College, London, UK
Cancer Treat Rev 28:157-9. 2002
High versus low doses of unfractionated heparin for the treatment of superficial thrombophlebitis of the leg. A prospective, controlled, randomized studyAntonio Marchiori
Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, University Hospital of Padua, Italy
Haematologica 87:523-7. 2002....
Simplification of the diagnostic management of suspected deep vein thrombosisRoderik A Kraaijenhagen
Department of Vascular Medicine, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
Arch Intern Med 162:907-11. 2002..The combination of a low clinical pretest probability with a normal result of compression ultrasonography or the D-dimer assay appears to be equally safe in refuting the diagnosis of deep vein thrombosis...
Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolismVittorio Pengo
Department of Clinical and Experimental Medicine, Division of Clinical Cardiology, University Hospital of Padua, Padua, Italy
N Engl J Med 350:2257-64. 2004..70). CONCLUSIONS: CTPH is a relatively common, serious complication of pulmonary embolism. Diagnostic and therapeutic strategies for the early identification and prevention of CTPH are needed...
The long term clinical course of acute deep vein thrombosis of the arm: prospective cohort studyPaolo Prandoni
Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, University Hospital of Padua, Via Ospedale Civile 105, 35128 Padua, Italy
BMJ 329:484-5. 2004
The optimal long-term treatment of venous thromboembolismPaolo Prandoni
2nd Chair of Internal Medical and Surgical Sciences, University of Padua, Italy
Clin Adv Hematol Oncol 2:729-32. 2004
Subcutaneous unfractionated heparin compared with low-molecular-weight heparin for the initial treatment of venous thromboembolismEnrico Bernardi
Emergency Department, Azienda Ospedaliera di Padova, Padua, Italy
Curr Opin Pulm Med 11:363-7. 2005..The present review focuses on the relative values of low-molecular-weight heparin and subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism...
How I treat venous thromboembolism in patients with cancerPaolo Prandoni
Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, University of Padua, Via Ospedale Civile 105, 35128 Padua, Italy
Blood 106:4027-33. 2005..The evidence of lowered cancer mortality in patients on LMWH has stimulated renewed interest in these agents as antineoplastic drugs and raises the distinct possibility that cancer and thrombosis share common mechanisms...
Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatmentMaria Gabriella Santamaria
Sezione di Medicina Interna e Cardiovascolare, Dipartimento di Medicina Interna, , Via Enrico Dal Pozzo, 06123 Perugia, Italy
Thromb Res 116:301-6. 2005..The role of thrombophilia in the long-term management of venous thromboembolism should be addressed in prospective management studies...
The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort studyPaolo Prandoni
Scienze Mediche e Chirurgiche, Clinica Medica II, Universita di Padova, Italy
Blood 106:3049-54. 2005..The previous administration of heparin increases the rate of HIT...
Cancer and venous thromboembolismPaolo Prandoni
Department of Medical and Surgical Sciences, Second Chair of Internal Medicine, University of Padua, Padua, Italy
Lancet Oncol 6:401-10. 2005..However, the issue of whether screening for occult malignant disease ultimately improves prognosis and survival remains to be resolved...
Emerging strategies for treatment of venous thromboembolismPaolo Prandoni
University of Padua, Department of Medical and Surgical Sciences, 2nd Chair of Internal Medicine, Via Ospedale Civile 105, 35128, Padua, Italy
Expert Opin Emerg Drugs 10:87-94. 2005..They include anti-Xa inhibitors, such as pentasaccharide, and antithrombin inhibitors, such as ximelagatran...
The effect of low molecular weight heparin on survival in patients with advanced malignancyClara P W Klerk
Department of Vascular Medicine, Academic Medical Center F4 139, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
J Clin Oncol 23:2130-5. 2005..In a double-blind study, we evaluated the effect of low molecular weight heparin on survival in patients with advanced malignancy without venous thromboembolism...
Risk factors of recurrent venous thromboembolism: the role of residual vein thrombosisPaolo Prandoni
Department of Medical and Surgical Sciences, Second Chair of Internal Medicine University Hospital of Padua, Italy
Pathophysiol Haemost Thromb 33:351-3. 2003..4 (95% CI, 1.3 to 4.4; p =0.004) for persistent residual thrombosis versus early vein recanalization. In conclusion, residual venous thrombosis should be regarded as an important risk factor of recurrent thromboembolism...
Controversial issues in the diagnosis of venous thromboembolismPaolo Prandoni
Department of Medical and Surgical Sciences, Second Chair of Internal Medicine, University Hospital of Padua, Italy
Pathophysiol Haemost Thromb 33:311-3. 2003....
Warfarin versus low-molecular-weight heparin therapy in cancer patientsLeo R Zacharski
VA Medical and Regional Office Center, 215 North Main Street, White River Junction, Vermont 05009, USA
Oncologist 10:72-9. 2005..Further evaluation of the LMWHs for effects on cancer outcome is indicated...
Elastic stockings, hydroxyethylrutosides or both for the treatment of post-thrombotic syndromePaolo Prandoni
Thromb Haemost 93:183-5. 2005
Recurrent venous thromboembolism in men and womenGiancarlo Agnelli
N Engl J Med 351:2015-8; author reply 2015-8. 2004
Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trialPaolo Prandoni
Department of Medical and Surgical Sciences, University Hospital of Padua, Padua, Italy
Ann Intern Med 141:249-56. 2004..Because only limited evidence suggests that elastic stockings prevent the post-thrombotic syndrome in patients with symptomatic deep venous thrombosis (DVT), these stockings are not widely used...
Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort studyPaolo Simioni
Department of Medical and Surgical Sciences, Second Chair of Internal Medicine, University of Padua Medical School, Via Ospedale, 105 35128 Padua, Italy
Blood 99:1938-42. 2002..Screening families of symptomatic probands with the factor V Leiden mutation has the potential to identify those asymptomatic carriers who might benefit from thromboprophylaxis during risk periods...
